Overview

Price chart · mood · technical indicators

OGN

Organon & Costock Healthcare

Drug Manufacturers - General

$13.2745.29%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$5.69$13.39

Current: $13.27

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

OGN

+45.29%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio14.14Forward 5.09

EPS (TTM)$0.9466.7% YoY

Profit margin4.0%HEALTHCARE

Market cap$3.49BMid cap

Wall Street coverage

$11.25median target· current $20.68 (-45.6%)5 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 5.09
PEG ratio: —
P/B: 4.64
P/S (TTM): 0.57
EV/EBITDA: 11.25

Profitability & growth

ROE (TTM): 30.6%
Operating margin: 18.7%
Revenue growth YoY: -3.5%
Dividend yield: 0.6%
Beta: 1.55

Last earnings

Apr 30, 2026 · Estimate $0.85 · Reported $0.71

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Organon & Co

Company profile

Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE
Country: USA
Currency: USD

Company profile

HQ: 30 HUDSON STREET, JERSEY CITY, NJ
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$3.49B

Shares outstanding$262.6M

52W high$13.39

52W low$5.69

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

OGN

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Organon & Co. 1Q 2026: Revenue $1.46B, EPS $0.55— 10-Q Summary

Mitsubishi UFJ Trust & Banking Corp Sells 202,370 Shares of Organon & Co. $OGN

Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates

Organon & Co. (NYSE:OGN) Short Interest Update

Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates

Sun Pharma To Acquire Former Merck Spinoff, Organon for $11.75 Bn

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon: Q1 Earnings Snapshot

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

Europe authorizes first PERJETA biosimilar for certain breast cancers

White & Case advises Sun Pharma on US$11.75 billion acquisition of Organon

Sun Pharmaceutical is buying Organon in an $11.75 billion all-cash deal

Sun Pharma Aims for Top 3 in Women’s Health with $11.75B Organon Purchase

Sun Pharma to Acquire Organon in $11.75 Billion Deal

Sun Pharma Signs Definitive Agreement to Acquire Organon

Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon

Sun Pharma to Acquire Organon in $11.75 Billion Deal

Organon Stock Soars After Sun Seals Takeover. Why Pharma M&A Is a Hot Play.

India’s Sun Pharma to buy US-listed Organon in about $11.8 billion deal

About Organon & Co

Classification

Company profile

OGN

Market Comparison

OGN Market Analysis

Overview

OGN

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Organon & Co. 1Q 2026: Revenue $1.46B, EPS $0.55— 10-Q Summary

Mitsubishi UFJ Trust & Banking Corp Sells 202,370 Shares of Organon & Co. $OGN

Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates

Organon & Co. (NYSE:OGN) Short Interest Update

Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates

Sun Pharma To Acquire Former Merck Spinoff, Organon for $11.75 Bn

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon: Q1 Earnings Snapshot

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

Europe authorizes first PERJETA biosimilar for certain breast cancers

White & Case advises Sun Pharma on US$11.75 billion acquisition of Organon

Sun Pharmaceutical is buying Organon in an $11.75 billion all-cash deal

Sun Pharma Aims for Top 3 in Women’s Health with $11.75B Organon Purchase

Sun Pharma to Acquire Organon in $11.75 Billion Deal

Sun Pharma Signs Definitive Agreement to Acquire Organon

Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon

Sun Pharma to Acquire Organon in $11.75 Billion Deal

Organon Stock Soars After Sun Seals Takeover. Why Pharma M&A Is a Hot Play.

India’s Sun Pharma to buy US-listed Organon in about $11.8 billion deal

About Organon & Co

Classification

Company profile

OGN

Market Comparison